Stay updated with breaking news from Torge Rempe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A novel biosimilar matches natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing remitting multiple sclerosis, results from a new phase 3 trial show.
New recommendations help clinicians communicate technical information to help patients with multiple sclerosis achieve better understanding and self-care.
Young and healthy 26-year-old woman suffered brain inflammation called CNS lymphocytic vasculitis after mild COVID-19 infection and underwent a series of corticosteroid-based treatments. After six months, the lesions decreased and no new lesions had formed.